These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 24112453

  • 21. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S.
    Thromb Haemost; 2014 Apr 01; 111(4):575-82. PubMed ID: 24452881
    [Abstract] [Full Text] [Related]

  • 22. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I.
    Farm Hosp; 2009 Apr 01; 33(3):125-33. PubMed ID: 19712596
    [Abstract] [Full Text] [Related]

  • 23. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY, Kim RB.
    Can J Cardiol; 2013 Jul 01; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [Abstract] [Full Text] [Related]

  • 24. New oral anticoagulants in development: potential for improved safety profiles.
    Bauer KA.
    Rev Neurol Dis; 2010 Jul 01; 7(1):1-8. PubMed ID: 20410856
    [Abstract] [Full Text] [Related]

  • 25. Perioperative management of patients on new oral anticoagulants.
    Lai A, Davidson N, Galloway SW, Thachil J.
    Br J Surg; 2014 Jun 01; 101(7):742-9. PubMed ID: 24777590
    [Abstract] [Full Text] [Related]

  • 26. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S, Samama MM.
    J Mal Vasc; 2014 May 01; 39(3):183-94. PubMed ID: 24650612
    [Abstract] [Full Text] [Related]

  • 27. Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
    Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G.
    Expert Opin Pharmacother; 2011 Mar 01; 12(4):567-77. PubMed ID: 21254865
    [Abstract] [Full Text] [Related]

  • 28. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH.
    Clin Lab Med; 2014 Sep 01; 34(3):443-52. PubMed ID: 25168936
    [Abstract] [Full Text] [Related]

  • 29. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI, Quinlan DJ, Eikelboom JW.
    Annu Rev Med; 2011 Sep 01; 62():41-57. PubMed ID: 21226611
    [Abstract] [Full Text] [Related]

  • 30. New anticoagulants for the prevention of thromboembolism.
    Lepic K, Crowther M.
    Curr Pharm Des; 2010 Sep 01; 16(31):3472-4. PubMed ID: 20858184
    [Abstract] [Full Text] [Related]

  • 31. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun 01; 22(139):155-9. PubMed ID: 23866358
    [Abstract] [Full Text] [Related]

  • 32. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
    Ufer M.
    Thromb Haemost; 2010 Mar 01; 103(3):572-85. PubMed ID: 20135071
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T, Gulseth M.
    Ann Pharmacother; 2013 Nov 01; 47(11):1478-87. PubMed ID: 24259602
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.